세계의 체외수정(IVF) 유전 위험 점수(GRS) 시장 : 예측 - 검사 유형별, 기술별, 용도별, 최종 사용자별, 지역별 분석(-2032년)

According to Stratistics MRC, the Global IVF Genetic Risk Scoring Market is accounted for $363.2 million in 2025 and is expected to reach $881.3 million by 2032 growing at a CAGR of 13.5% during the forecast period. IVF Genetic Risk Scoring (GRS) is a cutting-edge reproductive technology that evaluates the genetic health of embryos created through in vitro fertilization (IVF). By analyzing specific genetic markers, single-nucleotide polymorphisms (SNPs), and polygenic risk factors, GRS predicts the likelihood of an embryo developing certain inherited diseases or conditions later in life. This scoring system enables clinicians and prospective parents to make informed decisions about embryo selection, aiming to improve the chances of a healthy pregnancy and reduce the risk of genetic disorders. IVF GRS integrates advanced genomics, bioinformatics, and reproductive medicine to personalize fertility care with greater precision and foresight.

Market Dynamics:

Driver:

Advancements in Reproductive Technologies

Rapid innovations in genomics, bioinformatics, and embryo screening are propelling the adoption of IVF Genetic Risk Scoring (GRS). Enhanced precision in detecting polygenic risk factors and single-nucleotide polymorphisms (SNPs) enables clinicians to personalize embryo selection with greater confidence. Integration of AI-driven analytics and next-generation sequencing (NGS) platforms is further improving predictive accuracy, making GRS a cornerstone of modern fertility care. These advancements are driving market expansion by elevating clinical outcomes and reducing the incidence of inherited disorders.

Restraint:

High Cost and Limited Accessibility

High cost and limited accessibility significantly hinder the growth of the IVF genetic risk scoring market by restricting adoption to affluent urban centers. These barriers exclude vast populations from early-stage genomic screening, stalling equitable healthcare innovation. The lack of insurance coverage and infrastructure in emerging regions further exacerbates disparities, curbing demand and slowing clinical integration. As a result, market expansion remains constrained, with transformative potential unrealized across underserved geographies.

Opportunity:

Rising Incidence of Genetic Disorders

The increasing prevalence of hereditary conditions such as cystic fibrosis, Tay-Sachs, and BRCA-related cancers is intensifying demand for predictive embryo screening. IVF Genetic Risk Scoring offers a proactive solution by enabling early identification of genetic predispositions, thereby improving reproductive decision-making. As awareness grows among clinicians and prospective parents, GRS is poised to become a standard component of fertility protocols. This rising clinical need presents a significant growth opportunity, especially in regions with high rates of inherited diseases.

Threat:

Risk of Embryo Damage

The risk of embryo damage during genetic testing significantly undermines confidence in IVF genetic risk scoring, deterring adoption among clinicians and prospective parents. Concerns over invasive biopsy techniques and potential harm to viable embryos raise ethical and safety alarms, stalling regulatory approvals and investor interest. This uncertainty hampers market growth, limits clinical integration, and fuels public skepticism, especially in regions with conservative reproductive policies and limited genomic literacy.

Covid-19 Impact

The COVID-19 pandemic disrupted the IVF Genetic Risk Scoring market by halting fertility treatments, delaying embryo transfers, and increasing emotional stress for patients. Clinics paused operations during lockdowns, leading to postponed cycles and reduced demand. However, the crisis accelerated digital consultations and genomic screening awareness, fostering long-term growth. As services resumed, heightened interest in personalized embryo selection and genetic profiling positioned the market for resilient recovery and innovation.

The trait screening segment is expected to be the largest during the forecast period

The trait screening segment is expected to account for the largest market share during the forecast period, due to its broad clinical utility in assessing polygenic risks and inherited conditions. By analyzing specific genetic markers, this segment enables early detection of traits linked to chronic diseases, cognitive disorders, and physical anomalies. Its non-invasive nature and compatibility with existing IVF workflows make it highly scalable. As personalized medicine gains traction, trait screening is becoming integral to embryo selection, driving its leadership in market share.

The fertility clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the fertility clinics segment is predicted to witness the highest growth rate, due to rising demand for integrated reproductive services. These clinics offer end-to-end IVF solutions, including genetic counseling, embryo screening, and personalized treatment plans. Their adoption of advanced GRS platforms enhances patient outcomes and boosts clinical efficiency. As awareness of genetic risk scoring grows, fertility clinics are emerging as key distribution channels, particularly in urban centers with high patient volumes and advanced lab capabilities.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to its expanding fertility infrastructure, rising awareness of genetic disorders, and supportive government initiatives. Countries like China, India, and Japan are witnessing increased IVF adoption, driven by demographic shifts and growing middle-class affordability. Regional investments in genomics and digital health are further accelerating GRS integration. The presence of leading fertility clinics and research institutions positions Asia Pacific as a dominant force in the global IVF GRS landscape.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to robust healthcare infrastructure, high patient awareness, and strong regulatory support for genetic testing. The region's early adoption of precision medicine and advanced IVF protocols makes it fertile ground for GRS expansion. Strategic collaborations between biotech firms and fertility centers are enhancing innovation and accessibility. Favorable reimbursement policies and growing demand for personalized reproductive care are expected to sustain North America's leadership in market growth.

Key players in the market

Some of the key players profiled in the IVF Genetic Risk Scoring Market include Illumina, Inc., Agilent Technologies, Inc., Natera, Inc., CooperSurgical, Inc., Thermo Fisher Scientific, Inc., Vitrolife AB, Igenomix, Genea Limited, PerkinElmer, Inc., Quest Diagnostics Incorporated, Invicta Genetics, Juno Genetics, US Inc., Bioarray S.L., Reproductive Health Science Ltd. and Genesis Genetics Ltd.

Key Developments:

In July 2025, Thermo Fisher Scientific has agreed to acquire Sanofi's sterile manufacturing site in Ridgefield, New Jersey. This expansion aims to bolster U.S. drug product manufacturing capabilities, enhancing capacity to meet the increasing demand from pharmaceutical and biotech customers.

In July 2020, PerkinElmer partnered with Sonora Quest Laboratories to expand COVID-19 testing in Arizona. This collaboration aimed to increase testing capacity in response to rising case numbers, supported by funding from the state of Arizona.

Test Types Covered:

• Single-Gene Risk Scoring
• Polygenic Risk Scoring
• Carrier Screening Panels
• Whole Genome Sequencing

Technologies Covered:

• NGS (Next-Generation Sequencing)
• Microarray
• PCR-Based Methods
• AI & Machine Learning Algorithms

Applications Covered:

• Embryo Selection
• Disease Risk Prediction
• Trait Screening
• Personalized IVF Protocols
• Other Applications

End Users Covered:

• Fertility Clinics
• IVF Centers
• Genetic Counseling Firms
• Research Institutes

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Technology Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global IVF Genetic Risk Scoring Market, By Test Type

• 5.1 Introduction
• 5.2 Single-Gene Risk Scoring
• 5.3 Polygenic Risk Scoring
• 5.4 Carrier Screening Panels
• 5.5 Whole Genome Sequencing

6 Global IVF Genetic Risk Scoring Market, By Technology

• 6.1 Introduction
• 6.2 NGS (Next-Generation Sequencing)
• 6.3 Microarray
• 6.4 PCR-Based Methods
• 6.5 AI & Machine Learning Algorithms

7 Global IVF Genetic Risk Scoring Market, By Application

• 7.1 Introduction
• 7.2 Embryo Selection
• 7.3 Disease Risk Prediction
• 7.4 Trait Screening
• 7.5 Personalized IVF Protocols
• 7.6 Other Applications

8 Global IVF Genetic Risk Scoring Market, By End User

• 8.1 Introduction
• 8.2 Fertility Clinics
• 8.3 IVF Centers
• 8.4 Genetic Counseling Firms
• 8.5 Research Institutes

9 Global IVF Genetic Risk Scoring Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Illumina, Inc.
• 11.2 Agilent Technologies, Inc.
• 11.3 Natera, Inc.
• 11.4 CooperSurgical, Inc.
• 11.5 Thermo Fisher Scientific, Inc.
• 11.6 Vitrolife AB
• 11.7 Igenomix
• 11.8 Genea Limited
• 11.9 PerkinElmer, Inc.
• 11.10 Quest Diagnostics Incorporated
• 11.11 Invicta Genetics
• 11.12 Juno Genetics, US Inc.
• 11.13 Bioarray S.L.
• 11.14 Reproductive Health Science Ltd.
• 11.15 Genesis Genetics Ltd.